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Abstract:  Integrase  (IN)  is  a  clinically  validated  target  for  the  treatment  of  human 
immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The 
next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment 
failure and mutations within the IN coding sequence appear to confer cross-resistance. The 
characterization of those mutations is critical for the development of second generation IN 
inhibitors to overcome resistance. This review focuses on IN resistance based on structural 
and  biochemical  data,  and  on  the  role  of  the  IN  flexible  loop  i.e.,  between  residues  
G140-G149 in drug action and resistance. 
Keywords:  AIDS;  HIV-1  integrase;  Raltegravir;  Elvitegravir;  GSK-1349572;  
GSK-1265744; interfacial inhibitors; resistance 
 
1. Background 
During replication of the human immunodeficiency virus type 1 (HIV-1, Figure 1), integrase (IN) 
plays key roles at various steps of the replicative cycle [1]. In addition to its integration activity, IN 
interacts with the viral reverse transcriptase (RT) and can regulate the reverse transcription process [2].  
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Figure 1. HIV-1 life cycle. HIV-1 first binds cells via interactions between the viral glycoproteins gp120/gp41 
and  the  cellular  receptor  CD4  and  CCR5  or  CXCR4  co-receptors.  After  a  conformational  change  of  the 
complex,  gp41  allows  the  fusion  of  both  viral  and  cellular  membranes,  leading  to  the  release  within  the 
cytoplasm of the viral core. The viral RNA (two copies of single-stranded RNA) is reverse-transcribed by the 
viral reverse transcriptase (RT) into double-stranded DNA. This DNA is then processed by the viral integrase 
(IN) and organized within a large nucleoprotein complex, the pre-integration complex (PIC). Following nuclear 
translocation, IN catalyzes the integration of this same DNA within the host genome (strand transfer, ST). After 
transcription, the viral RNA can be exported as genomic RNA (non-spliced) or as mRNAs (spliced RNA). The 
spliced RNA is translated into viral polyproteins that are cleaved by the viral protease (PR) and associate with 
genomic RNA at the cell membrane. Maturation by PR leads to new infectious particles released from the 
infected cell by budding. Drug targets include four different steps of viral replication: entry/fusion, reverse 
transcription, integration, and maturation (red). (Adapted from [3]). 
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For this reason, mutations within the IN coding region of the pol gene can alter not only integration 
but also other steps in virus replication. Here, we will only focus on the reactions catalyzed directly by 
IN (Figure 2). 
Figure 2. The integration process. IN catalyzes the integration of the HIV DNA within the 
cellular  DNA  in  two  distinct  steps.  First,  IN  cleaves  the  dinucleotide  GT  at  both  3’ 
extremities of the viral DNA (red) by 3’-processing (3’-P). After nuclear import, the strand 
transfer (ST) reaction leads to the integration of the viral DNA (green) into the cellular 
DNA  (blue).  Cellular  proteins  then  repair  the  newly  created  junctions,  cleave  the 
overhangs and fill the gaps, duplicating five bases of the cellular DNA on each side. 
 
 
IN catalytic activity takes place following reverse transcription (Figure 1), as it associates with the 
long terminal repeats (LTR) of the newly synthesized viral DNA ends at the motif CAGT (Figure 2) 
[3-5]. A water molecule is used as the nucleophile to cleave the terminal dinucleotide GT. This first 
transesterification,  3’-processing  (3’-P),  takes  place  in  the  cytoplasm  of  the  infected  cell  and  is 
catalyzed  by  at  least  a dimer  of IN  [6] within a large nucleoprotein complex, the pre-integration 
complex  (PIC),  which  includes  viral  and  cellular  co-factors  in  addition  to  IN  and  the  reverse-
transcribed viral DNA [7,8]. The PIC migrates to the nucleus via the microtubule network and through 
a nuclear pore [9]. In the nucleus, the PIC targets the host DNA mainly in transcribing regions. This 
targeting is directed by cellular co-factors such as LEDGF/p75 [10-12]. The integration of both viral 
DNA ends, or concerted integration, occurs with a five base pair stagger on opposite strands of the 
genomic DNA (Figure 2) [4]. This second transesterification, also called strand transfer (ST), uses the Viruses 2010, 2                                       
 
 
1350 
free 3’-OH extremity of the viral DNA as the nucleophile to attack the target DNA within at least a 
tetramer of IN [6]. The final process of integration is the repair of the junctions between the viral and 
host DNA, probably by cellular proteins. Both 3’-P and ST activities can be reproduced biochemically 
with recombinant IN and oligonucleotides mimicking the viral LTR [13-15]. 
2. Integrase structure 
IN is a 32 kDa protein. It belongs to the nuclease-transposase superfamilly including RNase H, Ruv 
C, transposases and other retroviral integrases. HIV-1 IN contains 288 amino acids forming three 
domains (Figure 3A). The N-terminal domain (NTD) contains amino acids 1-49 and a zinc-binding 
motif H12H16C40C43 involved in the oligomerization of IN. The central catalytic core domain (CCD) 
contains amino acids 50-212 and harbors the catalytic DDE motif (D64D116E152) well conserved among 
the retroviral integrase superfamily [16]. This triad coordinates two metal co-factors required for DNA 
binding. In biochemical assays, the recombinant enzyme can use either Mn
2+ or Mg
2+ but Mg
2+ is the 
likely physiological cation. The C-terminus domain (CTD) contains amino acids 213-288 and carries a 
SH3-like domain implicated in DNA binding. 
Even if the structure of the whole protein has not been resolved yet, several crystals of the isolated 
domains [17-19] or combinations of two domains of IN [20,21] have been obtained. All three domains 
of IN form homodimers in solution. They are also all involved in the binding of both viral and cellular 
DNA. Those crystal structures and electron microscopy have allowed the modeling of the global shape 
of HIV-1 IN [22,23]. 
The catalytic site of HIV-1 IN has still not been resolved in the presence of DNA. Moreover, a 
flexible loop close to the active site, comprising amino acids 140-149, with poor diffraction properties, 
was originally only resolved when mutated (G140A+G149A) [18]. A crystal containing a dimer of the 
IN catalytic core in complex with IBD (IN Binding Domain of LEDGF/p75) showed the structure of 
the WT flexible loop in one of the IN subunits (Figure 3B) [24]. Recently, an NMR structure of a 
dimer of the core IN provided further information on the flexible loop structure [25]. Using chemical 
crosslinking and modeling, the flexible loop, which is crucial for IN activity appears to be in close 
contact with the non-cleaved strand of the viral DNA (GTCA-5’, Figure 2) [23,26-30] and residues 
Y143 and Q148 interact with the 5’-terminal CA overhang [23,26,27,30]. Based on modeling of the 
murine leukemia virus (MLV) IN, the flexible loop has been proposed to open and stabilize the 5’ 
overhang of the double-stranded viral DNA extremity to allow ST after 3’-P [31]. 
Very recently, the complete structure of the prototype foamy virus (PFV) IN has been resolved in 
complex with a short oligonucleotide substrate that mimics the viral DNA end after 3’-P, providing the 
first three-dimensional structure of an active IN active site [32]. PFV IN differs from HIV-1 IN by the 
presence of an N-terminal extension domain (NED), which is conserved among the spumaviral and 
gammaretroviral INs (Figure 3A) [4,33]. This extra domain is implicated in non-specific DNA binding 
to the phosphodiester backbone of the viral LTR. The rest of the PFV IN protein is globally very 
similar to HIV-1 IN (Figure 3). The integration signature of PFV IN is different from that of HIV-1 IN 
(4 base pair duplication for PFV instead of 5 for HIV) [33]. Nevertheless, raltegravir and elvitegravir 
also inhibit PFV IN in vitro [33], indicating that the active site of the PFV and HIV enzymes are quite 
similar. Several crystal structure of PFV IN are now available with either Mg
2+ or Mn
2+ and without a Viruses 2010, 2                                       
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metal co-factor (apo-enzyme) [32]. They show the importance of the flexible loop in binding and 
distorting the viral DNA to allow the attack of the 3’ LTR extremity on the target DNA during ST. 
Also, the flexible loop appears involved in RAL and EVG binding, highlighting a crucial role of the 
flexible loop in both IN activity and drug resistance [32]. From examination of the flexible loop region 
of several retroviral INs, PFV IN appears close to HIV-1 IN (Figure 4) with six out of 10 identical 
amino acids. A recent NMR study using the HIV-1 IN core domain showed that the HIV-1 and PFV 
INs flexible loops are highly similar [25]. The similarities between PFV and HIV legitimate the use of 
PFV IN as a model for HIV-1 IN. 
Figure 3. HIV-1 and PFV IN structures. A. Comparison of the primary structures of HIV-
1 and PFV IN. N-terminal (NTD) and C-terminal domains (CTD) are represented in light 
gray and catalytic core domains (CCD) in dark gray. The DDE motif is colored in red and 
mutations conferring resistance to RAL (positions 143, 148 and 155 for HIV-1; 212, 217 
and 224 for PFV IN) are highlighted in blue. The flexible loop, comprising amino acids 
140-149 for HIV-1 IN or 209-218 for PFV IN, is colored in green. B. Three-dimensional 
structure of HIV-1 and PFV IN core domains. Colors correspond to scheme A. In addition, 
amino acids 92 and 140 for HIV-1 IN and 161 and 209 for PFV IN are highlighted in light 
blue. Cartoon representations were obtained using MacPyMol version 0.99rc6 and the pdb 
file 2B4F (HIV-1 IN core domain, residue 57-207, with mutations F185K) and 3L2R (PFV 
IN complete structure with viral DNA and Mg/ Zn cations, residue represented 123-269). 
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Figure 4. Amino acid alignment of the flexible loop region from different retroviruses. 
Alignment of the amino acid sequences corresponding to the region around the flexible 
loop  of  HIV-1,  simian  immunodeficiency  virus  (SIV),  FIV,  avian/Rous  sarcoma  virus 
ASV/RSV, xenotropic murine leukemia-related retrovirus (XMRV) and PFV. The flexible 
loop region is shaded in green. Residues identical in all the retroviruses are colored in red, 
and  conserved  residues  with  only  one  amino  acid  difference  existing  between  the 
retroviruses  are  colored  in  blue.  Numbers  refer  to the first  residue for each sequence. 
Numbering at  the top of the alignment corresponds to HIV-1 IN residues involved in 
resistance to RAL and to the catalytic glutamic acid (E152). Numbering for PFV IN is 
reported underneath the alignment. 
 
3. Integrase inhibitors: historical overview 
Using biochemical assays, several classes of IN inhibitors have been discovered over the past 17 
years [1,34-36]. Hydroxylated natural products like dihydroxynaphtoquinones, isoflavones, chicoric 
acid and caffeic acid were reported in early biochemical studies [14,37]. Derivatives were developed 
(CAPE, 5-CITEP, V-165) and the most important family of inhibitors that emerged was the diketo 
acids (DKA) [38]. L-870,810 (Merck & Co.) and S-1360 (Shionogi & Co. Ltd. and GlaxoSmithKline) 
were  the  first  DKA-like  IN  inhibitors  to  reach  clinical  trials.  DKA  derivatives  are  ST-selective 
inhibitors (INSTI) with high specificity for IN-DNA complexes and antiviral activity. Clinical trials 
with S-1360 and L-870,810 were terminated in phase I/II and II due to limited efficacy and toxicity, 
respectively [34,35]. Peptides and nucleic acid inhibitors of IN in vitro have also been identified by 
screening (phage display, yeast 2-hybrids, SELEX) or rational design (derived from viral or cellular 
co-factors)  [39,40].  Zintevir  (AR177)  (Aronex  Pharmaceuticals)  is  a  G-quadraduplex-forming 
oligonucleotide  inhibitor  of  both  recombinant  IN  and  HIV-1  replication  at  low  nanomolar 
concentration [41,42]. It entered clinical trials in 1996, before the DKA, but was shown to target viral 
entry in cells and clinical trials were discontinued [43,44]. 
4. Raltegravir 
After years of sustained effort, Merck and Co. successfully developed raltegravir (RAL, Isentress® 
also known as MK-0518), which was approved by the FDA in late 2007 as the first IN inhibitor 
(Table 1). As for DKA, RAL’s inhibition mechanism is specific for the ST step of integration and 
proposed to involve chelation of one or two metals within the IN active site after processing of the 
bound viral DNA ends [45,46]. Viruses 2010, 2                                       
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Table 1. INSTI currently in clinical trials. 
Name  Company  Structure  Anti-
IN
a 
Anti-
HIV
b  T1/2  Status  Ref. 
Raltegravir 
MK-0518 
Isenstress® 
Merck & Co. 
 
2-7  8.9 
1; 
7-12 
FDA 
Approved 
October 
2007 
[35, 
47-
49] 
Elvitegravir 
JTK-303 
GS-9137 
Japan Tobacco 
Inc. and  
Gilead Sciences 
 
7  1.7  3; 9*  Phase III 
[35, 
47] 
S/GSK-
1349572 
ViiV-Healthcare 
and 
Shionogi & Co. 
Ltd 
 
N
O
N
CH3 O OH
O
H
N
O
F
F  
2.7  2  14  Phase IIb 
[35, 
50] 
a IC50 and 
b EC90 are expressed in nM. Half-life of compounds (T1/2) are expressed in h. 
* When boosted with ritonavir. 
 
Crystal structures obtained recently with RAL bound to the full length PFV IN confirmed the two 
metal binding mode (Figure 5A) [32]. Binding of RAL also induces a displacement of the viral DNA 
within the IN active site, moving the terminal 3’-A of the conserved CA by more than 6 Å from its 
original position [32]. RAL also makes Van Der Waals (VDW) interactions with the conserved CA 
dinucleotide and the fourth guanine from the end of the non-cleaved strand (base paired with the 
conserved C) (see Figure 2). In addition, RAL contacts several amino acids, including P214 and Q215 
(corresponding to P145 and Q146 for HIV-1 IN, respectively) by VDW interactions, and P214 (P145) 
by  hydrophobic  interaction  and  Y212  (Y143)  by  stacking  interaction.  RAL  also  forms  polar 
interactions with the catalytic triad (DDE) and the two Mg
2+ (Figure 5B). This mode of binding is 
consistent with the interfacial inhibition paradigm [3,51] whereby RAL was proposed to bind at the 
interface of IN and its DNA substrate following 3’-P. 
First used in regimen of heavily treated patients, RAL is now approved (since July 2009) for first 
line  therapy  in  combination  with  other  drugs  used  in  the  highly  active  anti-retroviral  therapy 
(HAART) combination regimen [52-56]. RAL has a remarkably low toxicity, exhibits high potency 
and  favorable  pharmacokinetics.  In  first  line  therapy,  the  oral  formulation  (400  mg  twice  a  day) 
induces a large decrease of viral RNA load below detection levels within a few weeks [57]. The main 
degradation pathway of RAL involves glucuronidation [48]. RAL’s half-life presents two phases: an Viruses 2010, 2                                       
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initial phase with a one hour half-life followed by a final phase with 7-12 hours half-life. An ongoing 
trial is also investigating the potential of a once-daily use of RAL (NCT00745823). 
5. IN mutations conferring RAL resistance 
Resistant  viruses  to  RAL  emerge  by  mutations  within  the  IN  coding  sequence,  which  clearly 
demonstrates that IN is the target of RAL. The biochemically characterized mutations are summarized 
in  Table  2,  and  an  extensive  list  of  IN  mutations  is  available  at 
http://ccrod.cancer.gov/confluence/display/LMPDNA/Home. Noticeably, the pattern of IN mutations 
for RAL overlaps with the previously reported mutations for the DKA derivatives (Table 2) [38,58]. 
Primary  mutations  involve  three  independent  and  non-overlapping  genetic  pathways:  mutation 
N155H, mutations Q148H/R/K and less frequently mutations Y143/R/C/H (Figure 3) [59,60]. These 
mutations also affect IN activity and viral replication (Table 2) [29,59,61,62]. Some mutations may 
involve integration-independent mechanisms. For example, the mutation Y143G has been reported to 
interfere with the completion of reverse transcription [62,63]. 
Additional  mutations  have  been  reported  including  V72I,  L74M,  E92Q,  T97A,  E138A/K, 
G140S/A,  V151I,  E157Q,  G163R/K,  D232N  [64-68].  Natural  polymorphism  studies  showed  that 
E157Q is present at a frequency of about 4-5%, while other mutations are highly infrequent [64]. 
Allele-specific real-time PCR has been used to detect very low levels of variants [69] and specific 
primers  to  amplify  mutations  Q148H,  Q148R  or  N155  (detection  limit  0.1%,  0.1%  and  0.05%, 
respectively). Before RAL exposure, the Q148R variant was detectable at low level (0.4% of the HIV 
pool) in most patients (81% in treatment experienced and 86% in naïve patients), but other mutations, 
Q148H and N155H, were not detectable [69]. 
Secondary  mutations  appear  specifically  for  each  primary  mutation:  secondary  mutations  at 
position E92 for either N155 or Y143, secondary mutation at position T97 for Y143, and secondary 
mutation at position G140 for Q148 (Table 2) [70]. These secondary mutations are likely to increase 
RAL resistance (E92) and/or restore defective IN activity and viral fitness (G140) resulting from the 
primary  mutations  (Figure  3)  [59,61].  The  double-mutation  at  positions  140  and  148  is  the  most 
common combination [59,70]. In patients, G140A tends to be associated with Q148R, and G140S with 
Q148H/K.  Systematic  biochemical  analyses  of  recombinant  IN  for  all  the  possible  combinations 
demonstrated that only the G140S-Q148H combination within the same IN polypeptide can rescue the 
biochemical  activity  of  IN  and  confer  high  resistance  to  RAL  [71].  In  agreement  with  these 
biochemical data, viruses harboring the double mutation G140S-Q148H exhibit high resistance to 
RAL (>1400-fold) and their replication capacity is close to WT (90% to 99%) (Table 2) [59,70]. For 
the  primary  mutation  N155H,  the  secondary  mutation  E92Q  markedly  increases  resistance  (from  
15-30-fold for N155H to around 500-fold for the double-mutant). However, it does not appear to 
rescue  viral  fitness,  which  remains  approximately  30  to  50%  of  WT  [59,70].  The  third  mutation 
pathway,  involving  position  Y143,  has  been  less  investigated.  It  seems  to  markedly  decrease  IN 
activities and viral fitness [62]. While 3’-P is affected for both Y143R and Y143C, the ST activity of 
Y143R is less affected than for the Y143C mutant. Even if such mutant viruses appear highly resistant 
to RAL, their low replication capacity may explain their delayed occurrence in patients [62]. Viruses 2010, 2                                       
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The order of appearance of mutant viruses may be related to two main parameters: the number of 
genetic  changes  needed  to  produce  the  specific  mutant  and  the  fitness/resistance  of  the  mutants. 
Mutations G140S/A, Y143C/H, Q148H/R/K and N155H require only one nucleotide change. On the 
other  hand,  mutation  Y143R  and  the  double  mutants  G140-Q148  require  two  genetic  alterations. 
Mutations at position 140 impair the ST activity (but not the 3’-P) without conferring resistance to 
RAL, and as a consequence do not present a selective advantage [71]. The mutation N155H leads to an 
active enzyme (and replicative virus) with an intermediate resistance to RAL (Table 2) [59]. This may 
explain why the pathway N155 appears first followed by the double-mutants 140-148 and the Y143R 
mutant. For mutations Y143C/H, only one substitution is required, but because of the defective IN in 
vitro activity and replication defect of the corresponding viruses [62], other mutations are probably 
required to rescue viral fitness and enhance resistance to RAL. The two mutations Y143C/H could 
also be a temporary path leading to Y143R, which has a better ST activity [62]. Even if mutations at 
position 143 can confer higher resistance to RAL than the double-mutant G140S-Q148H [62], the 
double-mutant G140S-Q148H presents a better enzymatic activity (almost at WT level in vitro and in 
vivo) [59,71,72], which may explain the prevalence of this double-mutation in RAL resistant viruses. 
Recently,  a  prospective  study  of  patients  receiving  RAL  showed  a  link  between  RAL  plasma 
concentration and the resistance pathway developed [73]. In patients developing resistance to RAL 
with mutation at position 155 and 143, the drug plasma concentration 12 h after tablet ingestion, 
corresponding to the lowest level of drug, was 50-100 ng/ml (100-200 nM) [73]. On the other hand, 
patients with mutations emerging at position 148 presented a higher level of RAL (300-350 ng/ml 
corresponding  to  750-800  nM)  [73].  RAL  has  a  limited  intestinal  absorption  [34]  and  resistance 
cannot  be  overcome  by  increasing  dosing.  Next  generation  drugs  are  warranted to overcome this 
pharmacological limitation and achieve high enough plasma concentrations to target RAL-resistant 
viruses. 
6. Elvitegravir 
Elvitegravir (EVG, GS-9137, JTK-303) is the next most advanced IN inhibitor. It is developed by 
Gilead Sciences and presently in phase III clinical trials (Table 1). In vitro, EVG exhibits potent anti-
IN and anti-HIV activity at low digit nanomolar IC50 and EC90 [34,74]. EVG is a slightly more potent 
IN inhibitor than RAL  [29,71]. However, it has also been reported to produce some non-specific 
toxicity  in  non-infected  cells  [34].  EVG  is  metabolized  in  vivo  by  cytochrome  P450  and 
glucuronidation  [48],  and  co-administration  with  ritonavir  (PR  inhibitor)  increases  EVG  systemic 
concentrations by about 20-fold, consistent with a possible once daily use of the drug [75]. Ongoing 
phase III studies are investigating the potential of EVG dosed at 125 mg once daily, boosted with 85 
mg of ritonavir (NCT00707733). Viruses 2010, 2                                       
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Figure 5.  Crystal structures of PFV IN in complex with INSTI. A. Three-dimensional 
structure of the PFV IN core domain in complex with its viral DNA substrate and RAL 
(left) or EVG (right) in the presence of magnesium. The core domain (amino acids 123-
269) is colored in grey. Positions 212, 217 and 224, corresponding positions 143, 148 and 
155  in  HIV-1  IN  are  highlighted  in  blue.  Positions  161  and  209,  corresponding  to 
secondary mutation positions 92 and 140 for HIV-1 IN, are highlighted in cyan. Cartoon 
representations were obtained using MacPyMol version 0.99rc6 and the pdb files 3L2T 
(RAL) and 3L2U (EVG) containing the PFV IN complete structure with viral DNA and 
Mg
2+/Zn
2+. B. Close view of the active site containing RAL (left) or EVG (right). Only the 
residues of PFV IN and the bases of the viral DNA within 5 Å of the drug are represented 
as sticks. Colors are similar to panel A. C. RAL (left) and EVG (right) chemical structures 
oriented as in the PFV IN structure in panel B. 
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Table 2. Characterized mutations within IN conferring resistance to RAL or EVG. 
  IN    Virus   
Mutations  3’-P  ST  R
ce    Selection  RC  Refs 
H51Y    ++      EVG    [76] 
H51Y/E92Q/S147G    +      EVG    [76] 
H51Y/E92Q/S147G/E157Q    ++      EVG    [76] 
T66A  +  ++      RAL/EVG  ++  [63,77,78] 
T66I  +++*  +++*  5
1-10
2X    DKA/EVG  ++*  [29,38,79-87] 
T66I/E92Q    -      EVG    [85,86] 
L74M  +++  +++  1X
1,2    DKA/EVG    [29,80,84,85,88] 
E92Q  +++*  +++*  4-5X
1,2    DKA/RAL/EVG  ++  [66,76,78,88] 
E92Q/S147G    +      EVG    [76] 
E92Q/N155H          RAL  ++*  [72,89] 
E138K/Q148HRK          DKA/RAL  ++  [72,87,90] 
G140S  +++*  +  1X
1,2    DKA/RAL  ++  [61,71,78,89-93] 
G140A  ++  +  2-3X
1    RAL    [71] 
G140S/Q148H  ++*  +++*  >50X
1,2    RAL  +++  [61,66,72,94] 
G140S/Q148K  ++  +  10-25X
1    DKA/RAL  ++  [71,72,90] 
G140S/Q148R  -  +  >25X
1    DKA/RAL  ++  [56,72,87] 
G140A/Q148H  -  +  >25X
1    RAL  +  [71,72] 
G140A/Q148K  -  -  2-3X
1    RAL  ++  [71,72] 
G140A/Q148R  +  +  >25X
1    RAL  ++  [71,72,95] 
G140S/Q148H/S230N          RAL  +++  [89] 
Y143R  +  ++  >50X
1    RAL  +  [56,62,93,96] 
Y143C  +  +  >50X
1    RAL  +  [62] 
Y143R/G163R          RAL  ++  [89] 
S147G    +      EVG    [76] 
Q148K  -  +*  50X
1*    DKA/RAL/EVG  +  [28,29,71,72,87,90] 
Q148R  +*  +  2-3X
1    DKA/RAL/EVG  ++  [71,72,78,85-87,90,95,97] 
Q148H  -  +*  2-3X
1,2    RAL  ++*  [61,71,72,78,89,93] 
Q148H/N155H          RAL  +  [89] 
Q148K/G163R          RAL    [87] 
N155H  +++*  +++*  5-10X
1,2    DKA/RAL  ++  [29,61,66,72,78,86,87,89,93-
95,97,98] 
E157Q    ++      RAL/EVG    [76,99] 
S230R  +++  +++      DKA/EVG    [80,85] 
R
ce: resistance expressed as fold change in IC50; RC: replication capacity. 
Signs  refer  to  activity  compared  to  WT:  -  =  0-10%;  +  =  10-40%;  ++  =  40-80%;  +++  =  80-100%;  
no entry = not tested. 
1 RAL, 
2 EVG, * discordant data in literature (the highest value is presented). Viruses 2010, 2                                       
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EVG resistance is associated with specific primary mutations such as T66I and S147G in addition 
to mutations common with RAL resistance (E92Q, Q148H/R/K and N155H) (Table 2) [64,67,76]. As 
for RAL, secondary mutations are selected under EVG exposure. Mutations H51Y, T66A/K, L68I/V, 
S119R/G, G140C, S153Y, K160N, R166S, E170A, S230R and R263K are specifically selected in 
addition to E138K, G140S, E157Q and D232N, which are common with RAL [67]. The resistance 
factor induced by the double-mutation G140S-Q148H is higher with EVG than with RAL [29,71]. 
Because EVG is slightly more potent than RAL (Table 1) and because its blood concentration can be 
boosted,  it  might  be  possible  higher  safe  doses  of  EVG  could  still  reach  an  active  concentration 
window in patients developing mutant viruses. 
Crystal structures obtained with the PFV IN show that EVG shares a common binding mode with 
RAL [32]. Similar to RAL, EVG binds as an interfacial inhibitor in the IN catalytic site. It presents 
VDW interactions with the conserved CA and the fourth G from the 3’-end of the non-cleaved strand 
and induces a displacement of the viral DNA. Regarding its drug-protein interactions, EVG exhibits 
closer interactions with P214 (corresponding to P145 in HIV-1 IN) [32]. Comparison of the RAL and 
EVG crystal structures shows that Y143, which harbors a stacking interaction with the oxadiazole ring 
of RAL, does not have as strong interaction with EVG (Figure 5B). Some  in vitro data seems to 
confirm that IN issued from RAL resistant viruses harboring mutation Y143 as primary signature 
present a limited resistance to EVG (i.e., smaller fold change) [73]. Thus, further studies are warranted 
to determine whether EVG remains active against the Y143 IN mutants that are selected by RAL 
exposure. 
7. Second generation INSTI 
New  promising  compounds  are  currently  under  phase  II  clinical  trials  [50].  Shionogi-
GlaxoSmithKline (S-GSK) Pharmaceuticals, LLC (USA) is developing new IN inhibitors that should 
be active against RAL- and EVG-resistant IN mutants. The lead compound, GSK-1349572 displays 
low nanomolar IC50 in vitro and very long half-life in humans (14 h, Table 1). Similarly to RAL and 
EVG, GSK-1349572 inhibition involves the chelation of divalent ions within the active site through a 
two-metal  binding  scaffold  [35,50].  The  inhibition  of  viral  replication  (sub-nanomolar  EC50)  is 
specific  for  the  integration  step,  with  a  total  viral  DNA  remaining  constant  in  the  cell  while  the 
integrated  DNA  decreases and circular 2-LTR viral  DNA  increases  [50]. GSK-1349572 seems to 
present  good  pharmacokinetics  (Table  1).  It  is  metabolized  through  UDP-glucoronosyltransferase 
(UGT) and its concentration can be decreased by certain multivitamin supplement or antacids [100]. 
Additionally, GSK-1349572 does not inhibit cytochrome P450 [50]. It also presents low inter-patient 
pharmacokinetics variability and reaches effective therapeutic concentrations even when used alone 
without boosting agent. 
Regarding resistance mutations, GSK-1349572 is still in early development and highly resistant 
viruses have not been characterized. In vitro selection showed a different mutation pattern compared to 
RAL and EVG [50]. Resistance mutation selected under GSK-1349572 exposure comprised L101I, 
T124A,  S153F/Y  with  four-fold  resistance.  When  assessed  against  previously  reported  mutants 
resistant to RAL and EVG, GSK-1349572 did not appear to show cross-resistance [50]. For example, 
single mutants containing either E92Q, Q148H/R/K, S153Y or N155H and double-mutants containing Viruses 2010, 2                                       
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E92Q-N155H or T97A-Y143R/C did not change the EC50 of the drug. However, the double-mutants 
G140S-Q148H/R exhibit 20-fold resistance to GSK-1349572. This improvement in term of resistance 
together with the slightly greater potency of GSK-1349572 compared to RAL may be sufficient for the 
drug to inhibit mutant virus replication. 
S-GSK Pharmaceuticals is also developing in parallel a backup compound, GSK-1265744, which is 
currently in phase I/IIa. GSK-1265744 presents similar inhibitory and pharmacokinetic properties to 
GSK-1349572 with an increased half-life (30 h) [55]. 
8. Conclusions 
Because of its central role in retroviral replication and of the effectiveness of RAL and EVG, IN is 
now a fully validated target for anti-HIV therapy. Before the approval of RAL, HIV-1 IN was not 
targeted with HAART. The good pharmacokinetics, minimal side effects and safety of RAL should 
allow its broad use in AIDS patients. EVG, the next most advanced IN inhibitor appears to share not 
only  the  same  inhibition  mechanism  but  also  cross-resistance  with  RAL.  It  is  likely  that  novel 
inhibitors such as the new drugs from S-GSK will overcome the RAL- and EVG-resistance mutations 
both by allowing more effective plasma concentrations and by acting at different sites of IN. The 
molecular  characterization  of  resistant  viruses  is  an  essential  step  for  the  discovery  and  the 
development of new IN inhibitors. 
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